SSY Group (HK:2005) has released an update.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
SSY Group Limited is excited to announce that their Nicorandil Tablets, used for treating angina, have received production and registration approval from China’s National Medical Products Administration. Following the Group’s previous success in registering Nicorandil as a bulk drug, this new advancement is communicated to shareholders and potential investors as part of the company’s commitment to updating on business progress.
For further insights into HK:2005 stock, check out TipRanks’ Stock Analysis page.